Outpatient Monoclonal Antibody (mAb) Therapeutics

As part of the COVID-19 response efforts, Health Resources and Services Administration’s (HRSA) Health Center Program is working in collaboration with Operation Warp Speed (OWS) and State Primary Care Associations (PCAs) to identify health centers to pilot the administration of outpatient monoclonal antibody (mAb) therapeutics to high-risk COVID-19 positive patients in outpatient settings. As of January 4, OWS has reported that 36 health centers have been allocated Bamlanivimab under the SPEED mAb Program in the following 21 states: Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, North Carolina, New Hampshire, New York, Ohio, Pennsylvania, Texas, Wisconsin and West Virginia.

Read more about mAb therapeutics.